0707 GMT - Fresenius Medical Care's surprise CEO change will be taken negatively by investors and points to a challenging outlook for the German dialysis specialist, analysts at J.P. Morgan say. The departure of CEO Helen Giza comes less than 18 months after she presented an ambitious business plan with guidance through 2030, the analysts say in a research note. Her exit suggests it is now less likely the company will be able to demonstrate the benefits from the rollout of a new dialysis technology in the U.S., they add. The end of regulatory tailwinds that recently flattered the group's results mean Fresenius Medical Care could be set for an operating profit contraction, according to JPM. Shares fall 2.7%.